Sinomab Bioscience Limited released its Monthly Return for the period ended 30 April 2026, confirming a stable share structure and continued compliance with Hong Kong Stock Exchange public-float requirements.

Issued Share Capital • Ordinary shares in issue remained at 1.39 billion, with no treasury shares recorded. • The company reported zero movements in issued or treasury shares during the month.

Public Float • Management affirmed that the minimum public-float threshold of 25% was met as at 30 April 2026.

Share Option Scheme • Under the 2022 Share Option Scheme (approved 26 October 2022 and amended 14 June 2024), 80.58 million options were outstanding at month-end, unchanged from March. • These options represent a potential 16.93 million new shares. • The total shares that may be issued under the scheme, including ungranted options, stood at 40.95 million. • No options were exercised, resulting in zero new shares issued and no funds raised during the month.

Other Securities • The company reported no outstanding warrants, convertibles, or other agreements to issue shares, and no buy-backs or cancellations occurred in April.

Governance Confirmation • Executive Director, Chairman and CEO Shui On Leung certified that all share-related activities complied with listing rules and regulatory requirements.

Overall, Sinomab Bioscience’s April filing highlights a steady capital base with no dilution events and full adherence to public-float and regulatory standards.